BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Biogen revealed on May 14, 2026, that the topline data from its Phase 2 CELIA study for diranersen failed to meet its primary endpoints. Based on these facts, the Company’s shares fell about 6.4% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
